Renal effects of canagliflozin in type 2 diabetes mellitus.

BACKGROUND
Chronic kidney disease is commonly associated with type 2 diabetes mellitus (T2DM) and may impact the efficacy and safety of glucose-lowering therapies. Canagliflozin, a sodium glucose co-transporter 2 inhibitor, reduces blood glucose levels in patients with T2DM by lowering the renal threshold for glucose, thereby promoting urinary glucose excretion. This review describes the pharmacology, efficacy and safety of canagliflozin according to kidney function in participants with T2DM.


METHODS
Published articles that reported efficacy, safety and pharmacokinetics/pharmacodynamics data for canagliflozin in patients with T2DM and impaired renal function, and renal safety data with canagliflozin in various populations of patients with T2DM through May 2015 were included.


RESULTS
Early transient reductions in estimated glomerular filtration rate were observed with canagliflozin; these changes generally stabilized or attenuated over time and reversed after discontinuation, suggesting no renal (glomerular or tubular) damage with canagliflozin treatment. Urinary albumin-to-creatinine ratios were reduced with canagliflozin. Canagliflozin was generally well tolerated in patients with normal or mild to moderately impaired renal function, with a modestly higher incidence of renal-related adverse events and volume depletion-related adverse events in patients with moderate renal impairment. Adverse events related to potassium elevations were infrequent with canagliflozin 100 mg regardless of kidney function status; however, patients with moderately impaired kidney function experienced hyperkalemia more frequently with canagliflozin 300 mg compared with patients treated with either canagliflozin 100 mg or placebo. Canagliflozin was not associated with increased cardiovascular risk across studies; however, relatively few events among patients with impaired renal function meant that the analysis was not adequately powered to examine this outcome, and results from separate trials are awaited.


CONCLUSIONS
Overall, canagliflozin is associated with small, transient changes in kidney function, and is well tolerated in patients with T2DM with varying kidney function status.


Introduction
Chronic kidney disease (CKD) is one of the most important challenges in patients with type 2 diabetes mellitus (T2DM), as it affects more than 40% of all patients and more than 60% of patients over the age of 65 1 . People with T2DM and CKD have much higher mortality and morbidity rates than either condition alone 2 , which highlights the need for better treatments for affected individuals. T2DM is the most common cause of kidney failure that requires dialysis in the United States and in most developed countries 3 , and recent studies suggest that glucose control may have a key role in preventing kidney failure 4,5 . Therefore, it is important to understand the efficacy and safety of individual glucose-lowering therapies on the kidney in patients with varying baseline kidney function status.
Sodium glucose co-transporter 2 (SGLT2) inhibitors are a new class of drugs for the treatment of hyperglycemia in adults with T2DM 6 . Drugs in this class act on the kidney to lower blood glucose levels by lowering the renal threshold for glucose, which in turn increases urinary glucose excretion (UGE) and leads to a mild osmotic diuresis 6 . SGLT2 inhibitors have been associated with improvements in glycemic control, weight loss and blood pressure (BP) reductions in patients with T2DM 6 ; however, because the rate of UGE is proportional to glomerular filtration rate (GFR) as well as plasma glucose concentration 7,8 , the glucose-lowering efficacy of SGLT2 inhibitors may be reduced in patients with comorbid CKD.
Canagliflozin is approved in many countries as an adjunct to diet and exercise for improving glycemic control in adults with T2DM [9][10][11][12][13][14][15][16][17][18][19][20][21] . Although the renal excretion of canagliflozin is low 22 , the hemodynamic changes related to osmotic diuresis, reduction in BP and altered intrarenal hemodynamics (e.g., improved tubuloglomerular feedback) seen with canagliflozin may also contribute to changes in estimated GFR (eGFR). This review article summarizes the pharmacokinetics and pharmacodynamics of canagliflozin in patients with renal impairment, the effects of canagliflozin on the kidney in patients with T2DM across a range of levels of kidney function, including those with Stage 3 CKD, and the efficacy and important safety findings from randomized, Phase 3 studies of canagliflozin in a broad range of patients with T2DM and varying baseline kidney function status.

Effects of T2DM and SGLT2 inhibition on the kidney
In patients with T2DM, the filtered glucose load is increased, leading to increased reabsorption of glucose and sodium, which is further compounded by the upregulation of SGLT2 transporters 23 . These physiologic adaptations paradoxically sustain hyperglycemia and exacerbate the volume expansion that is characteristically seen in people with T2DM. Intravascular volume expansion contributes to elevated BP and renal hyperfiltration, as well as atrial stretch, which in turn activates the release of atrial natriuretic peptide (ANP), a contributor to altered intrarenal hemodynamics, leading to further hyperfiltration and compounding the observed renal abnormalities 24 .
Hyperfiltration in the early stages of diabetic nephropathy is associated with enhanced sodium reabsorption in the proximal renal tubule, which reduces sodium delivery to the juxtaglomerular apparatus (i.e., macula densa) 25 ; this impairs tubuloglomerular feedback and results in afferent arteriolar vasodilation, which leads to elevated intraglomerular pressure and increased GFR 23,26 . The net effect of these changes is volume expansion, increased BP and renal hyperfiltration, all of which increase the risk of kidney damage and progressive loss of kidney function.
The BP and blood glucose lowering achieved with SGLT2 inhibition are also likely to be beneficial in offsetting or reversing the progression of CKD 4,42-44 . Improving glycemic control has been shown to delay the progression of albuminuria 4 and may prevent end-stage renal disease (ESRD) 4,5 , while intensive BP lowering has been shown to confer renoprotection in patients with albuminuria; however, the effects in those without albuminuria remain uncertain 44 . Overall, SGLT2 inhibition induces a suite of changes in people with T2DM that suggests a strong likelihood of renoprotection.

Methods
This non-systematic review article reports efficacy, safety and pharmacokinetics/pharmacodynamics data for canagliflozin in patients with T2DM and impaired renal function, and renal safety data with canagliflozin in various populations of patients with T2DM published through May 2015. Data were summarized from published primary articles and pooled analyses of Phase 3 data from the canagliflozin clinical trial program, as well as from publicly available sources of canagliflozin data; select data were provided by the sponsor of canagliflozin (Janssen Research & Development, LLC).
Specific endpoints of interest included changes in eGFR, serum creatinine, blood urea nitrogen (BUN) and albumin/creatinine ratio, as well as renal safety (e.g., renalrelated adverse events [AEs]) and other safety outcomes    Effect on markers of diabetic nephropathy Phlorizin prevented increases in total kidney weight and proteinuria in diabetic rats 31 Empagliflozin attenuated increases in kidney weight, albuminuria, markers of kidney growth and markers of inflammation in diabetic mice 29,34 SGLT2 inhibitors, including luseogliflozin, empagliflozin and tofogliflozin, have shown improved markers of diabetic nephropathy in diabetic rats 32,33 Decreased proteinuria has been observed with SGLT2 inhibition in diabetic rodents 31,35 Canagliflozin provided reductions in ACR 14,16,18,19 Indirect effects SGLT2 inhibitors have been shown to improve parameters associated with reductions in measures of diabetic nephropathy, including hyperglycemia, blood pressure and weight in diabetic rats 7,28,29 SGLT2 inhibitors have been shown to improve parameters associated with reductions in measures of diabetic nephropathy, including hyperglycemia, blood pressure, weight and uric acid levels in diabetes [38][39][40] (e.g., hyperkalemia, AEs related to volume depletion, bone fractures, cardiovascular safety). This manuscript summarizes renal data from the pooled, placebo-controlled population, including patients with normal renal function from four placebo-controlled studies of canagliflozin 9,11-13 ; active-controlled studies of canagliflozin as add-on to metformin versus glimepiride and sitagliptin 11,14,18 and as add-on to metformin plus sulfonylurea versus sitagliptin 15 ; and a placebo-controlled study in older adults 17,20 ( Table 2). This manuscript also reports data from patients with impaired renal function, including those enrolled in a dedicated placebo-controlled study of canagliflozin in patients with moderate renal impairment 16,19 and a pooled population of patients with Stage 3 CKD who were enrolled in four placebo-controlled studies 9,16,17,47 (  48 . Compared with the normal renal function group, geometric mean values for systemic exposure to canagliflozin (AUC 1 ) were $7%, 63% and 50% higher, and mean maximum plasma concentrations (C max ) of canagliflozin were 13%, 29% and 29% higher in subjects with mild, moderate and severe renal impairment, respectively; exposure in subjects with ESRD was similar to those with normal renal function and may be related to clearance via hemodialysis in these patients 48 .
Despite the higher systemic exposure to canagliflozin in subjects with moderate and severe renal impairment, 24hour UGE decreased with declining renal function, consistent with the dependency of UGE on GFR 48 .

Renal effects of canagliflozin Overview
The canagliflozin clinical development program included placebo-and active-controlled studies that enrolled $10,000 patients in studies lasting 52 or 104 weeks, as well as in an ongoing long-term outcomes study [9][10][11][12][13][14][15][16][17][18][19][20][21] . Assessments of kidney function and safety were performed across these studies. This review summarizes renal data from individual placebo-and active-controlled studies of canagliflozin, as well as from pooled populations derived from these studies, which included patients with varying kidney function status (Table 2). Across studies, treatment with canagliflozin was generally associated with early reductions in eGFR of $4 mL/ min/1.73 m 2 (ranging from approximately À2 to À6 mL/ min/1.73 m 2 ), along with commensurate increases in serum creatinine (ranging from approximately 1-15 mmol/L [$0.01-0.2 mg/dL]) 9-20 . Treatment with canagliflozin was also associated with increases in BUN of approximately 1-4 mmol/L ($3-11 mg/dL) [9][10][11][12][13][14][15][16][17][18][19][20] . Across studies in various populations, the observed changes in eGFR were greatest at the first post-baseline visit ($3-6 weeks) and generally stabilized or attenuated within 26 weeks (Figure 2) 9-20 . Across the Phase 3 development program, eGFR and creatinine levels were not universally measured after trial completion; however, among a subset of patients who had renal function measurements subsequent to discontinuation of study drug (n ¼ 396), eGFR values increased toward baseline levels after discontinuation of canagliflozin treatment, demonstrating the reversibility of renal effects with canagliflozin ( Figure 3) 49 . Notably, studies of other agents in this class have assessed post-completion, off-treatment creatinine levels, and have also found that acute reductions in eGFR were reversible 50 .
The changes in renal hemodynamics observed with SGLT2 inhibition would be expected to lead to reduced intraglomerular pressure and therefore a reduction in albuminuria as part of the pathway to renoprotection. Indeed, reductions in albumin-to-creatinine ratio (ACR) were observed in the subset of canagliflozin studies in which ACR was assessed 14,16,18,19 , suggesting the possibility of renoprotection.

Renal effects of canagliflozin in patients with normal renal function
Placebo-controlled studies In the pooled, placebo-controlled population, larger reductions in eGFR and increases in serum creatinine and BUN were seen with canagliflozin 100 and 300 mg compared with placebo 46 . Maximal reductions in eGFR were seen across groups from baseline to Week 6, with a return toward baseline through Week 26; mean changes from baseline to Week 26 were À2.1, À3.1 and À1.2 mL/min/ 1.73 m 2 with canagliflozin 100 and 300 mg and placebo, respectively 46  reduction in eGFR at any time post-baseline, and neither of these patients had an eGFR reduction 450% at Week 26 46 .

Active-controlled studies
As add-on to metformin versus glimepiride, reductions in eGFR were seen at 4 weeks with canagliflozin 100 and 300 mg compared with glimepiride, consistent with the known acute effect of SGLT2 inhibitors (mean changes of À3.0, À5.8 and À1.2 mL/min/1.73 m 2 , respectively). Importantly, eGFR levels continued to decline during subsequent follow-up in the glimepiride-treated participants, but appeared to attenuate in those receiving canagliflozin.  Figure 2) 18 . By 52 weeks, reductions in eGFR with canagliflozin were generally similar to those seen with sitagliptin as add-on to metformin and as add-on to metformin plus sulfonylurea ( Figure 4) 11,15 .

Older patients
Older patients have a greater prevalence of CKD and, therefore, they may be more sensitive to renal changes induced by canagliflozin. In a placebo-controlled, Phase 3 study of canagliflozin in older patients with T2DM (55-80 years), changes in eGFR were similar to those seen in other placebo-controlled studies over 26 and 104 weeks 17,20 . The largest changes in eGFR and serum creatinine were observed at Week 6 and remained stable or returned toward baseline over 104 weeks (Figure 2). At Week 26, mean changes in eGFR from baseline were À2.5, À4.0 and À1.4 mL/min/1.73 m 2 with canagliflozin 100 and 300 mg and placebo, respectively 17 . Mean changes in eGFR at Week 104 (À3.1, À3.1 and À3.1 mL/min/ 1.73 m 2 with canagliflozin 100 and 300 mg and placebo, respectively) were similar to those seen at Week 26 20 . In a subgroup analysis of patients from the pooled, placebo-controlled population by age (565 vs !65 years), eGFR reductions were slightly larger in older (average baseline eGFR, $76-77 mL/min/1.73 m 2 ) versus younger patients (average baseline eGFR, $90-91 mL/ min/1.73 m 2 ) 51 . In both age groups, transient decreases in eGFR were observed with canagliflozin relative to placebo over the first 3-6 weeks of treatment; however, eGFR stabilized or attenuated over the 26-week treatment period. Over 26 weeks, in the canagliflozin 100 and 300 mg and placebo groups, respectively, LS mean changes in eGFR were À2.3, À3. 5

Overall efficacy
Canagliflozin was associated with reductions in HbA 1c and body weight compared with placebo in patients with Stage 3 CKD 16,19,45 , which were generally smaller than those seen in patients with normal or mildly impaired renal function [9][10][11][12][13][14][15]17 . In a pooled analysis that included data from patients with Stage 3 CKD (baseline eGFR !30 and 560 mL/min/1.73 m 2 ) from four placebo-controlled, Phase 3 studies, mean changes in HbA 1c from baseline were À0.38% and À0.47% with canagliflozin 100 and 300 mg versus placebo, respectively 45 . Higher percentages of patients with T2DM and Stage 3 CKD achieved HbA 1c 57.0% with either canagliflozin 100 or 300 mg compared with placebo, indicating clinically meaningful glycemic improvements 16,19,45 . In contrast, the BP-lowering effect appeared similar to that in people with preserved kidney function and may be related, in part, to renal mechanisms separate from increased UGE (e.g., sensitivity to the mild osmotic diuresis) 19 ; relative to placebo, systolic BP was reduced by À2.8 and À4.4 mmHg with canagliflozin 100 and 300 mg, respectively 45 . Canagliflozin was generally well tolerated in patients with Stage 3 CKD, with a safety profile similar to that seen in other canagliflozin Phase 3 studies (Table 3) 16,19,45 .

Renal effects
In the Phase 3 study of canagliflozin in patients with T2DM and moderate renal impairment (baseline eGFR !30 and550 mL/min/1.73 m 2 ) 16,19 , early transient reductions in eGFR were observed with canagliflozin 100 and 300 mg and placebo that were similar in magnitude (albeit larger on a percentage basis) to those in the general T2DM population and stabilized over time (Figure 2). At Week 52, mean changes in eGFR were À2.1, À4.0 and À1.6 mL/min/1.73 m 2 with canagliflozin 100 and 300 mg and placebo, respectively 19 . Canagliflozin 100 and 300 mg compared with placebo were associated with commensurate increases in serum creatinine (LS mean changes of 7.7, 15.8 and 6.2 mmol/L [0.08, 0.17 and 0.06 mg/dL], respectively) and in BUN (LS mean changes of 0.86, 1.35 and 0.04 mmol/L [2.7, 3.8 and 0.5 mg/dL], respectively) at Week 52 19 .
In the pooled, Stage 3 CKD population (baseline eGFR !30 and 560 mL/min/1.73 m 2 ), reductions in eGFR at Week 26 were larger with canagliflozin 100 and 300 mg compared with placebo (mean changes of À1.7, À2.2 and 0.7 mL/min/1.73 m 2 , respectively). Results were also analyzed in subgroups of patients with Stage 3A CKD (eGFR !45 and 560 mL/min/1.73 m 2 ; mean baseline eGFR, 53.3 mL/min/1.73 m 2 ) and Stage 3B CKD (eGFR !30 and 545 mL/min/1.73 m 2 ; mean baseline eGFR, 38.2 mL/ min/1.73 m 2 ) 45 . In the Stage 3A CKD subgroup, eGFR reductions at Week 26 were À1.4, À2.3 and 1.0 mL/min/ 1.73 m 2 with canagliflozin 100 and 300 mg and placebo, respectively; eGFR reductions at Week 26 were À2.4, À2.1 and 0.01 mL/min/1.73 m 2 , respectively, in the Stage 3B CKD subgroup 45 . In the overall Stage 3 CKD population and the Stage 3A and 3B CKD subgroups, a small initial decline in eGFR was seen with canagliflozin, followed by a return toward baseline, which is consistent with the trend observed in patients with normal renal function in other Phase 3 studies of canagliflozin. The proportion of patients with larger reductions in renal function was also small and similar across groups; few patients had eGFR reductions 450% from baseline (5/

Effects of canagliflozin on the albumin-tocreatinine ratio
Canagliflozin provided reductions in ACR in the subset of studies that assessed changes in ACR 14,16,18,19 . In the active-controlled study of canagliflozin as add-on to metformin versus glimepiride, which enrolled patients with normal or mildly impaired renal function, reductions in ACR were seen with canagliflozin 100 and 300 mg, whereas an increase was seen with glimepiride at Week 52 14 and Week 104 18 ( Figure 5). This result strongly suggests that the albuminuria-lowering effects are glucoseindependent. In the study of patients with moderate renal impairment (eGFR !30 and 550 mL/min/1.73 m 2 ), reductions in urinary albumin excretion and ACR were observed at Weeks 26 and 52 with both canagliflozin doses relative to placebo 16,19 .

Renal-related adverse events
The incidence of renal-related AEs (e.g., blood creatinine increased, renal impairment and GFR decreased) reported by investigators during the studies was low and similar across groups among the pooled, placebo-controlled population (0.6%, 1.7% and 0.6% with canagliflozin 100 and 300 mg and placebo, respectively; Table 4) 46 . In the pooled population of patients with Stage 3 CKD, the incidence of investigator-reported, renal-related AEs was higher with canagliflozin 100 and 300 mg compared with placebo (8.9%, 9.3% and 3.7%, respectively; Table 4) 45 .
In both pooled populations, the most common problems described by investigators included elevated blood creatinine, renal impairment and decreased GFR. Few renal-related AEs were deemed serious or led to study discontinuation.

Other safety findings
Canagliflozin is generally well tolerated; however, an increase in AEs related to SGLT2 inhibition (e.g., genital mycotic infections and urinary tract infections) with canagliflozin has been observed across studies [9][10][11][12][13][14][15][16][17][18][19][20][21] . These risks appear to be similar in people with T2DM who were treated with canagliflozin and had either normal kidney function or CKD. Findings related to other safety topics of interest (i.e., changes in potassium, volume depletionrelated AEs, bone fractures and cardiovascular safety) from canagliflozin studies in patients with and without renal impairment are described in the following sections.

Potassium
Small changes in serum electrolyte levels (e.g., potassium, magnesium and phosphate) have been previously reported in patients with T2DM, especially in patients with reduced eGFR and in patients treated with canagliflozin 300 mg 52,53 . In addition, comorbid hypertension is common in patients with T2DM, and treatment with ACE inhibitors, ARBs and/or potassium-sparing diuretics can interfere with potassium excretion, particularly in patients with reduced eGFR 53 . Thus, it is important to understand the potential effects of changes in renal function on the risk of potassium elevations that are associated with canagliflozin treatment.
In a pooled analysis based on renal function, mean baseline potassium levels were the same across groups in patients with eGFR !60 mL/min/1.73 m 2 (4.3 mmol/L for all) and eGFR !45 and 560 mL/min/1.73 m 2 (4.5 mmol/L for all). The proportions of patients who had potassium levels meeting outlier criteria (4upper limit of normal [ULN; 5.4 mmol/L] and 415% increase from baseline) at any time post-baseline with canagliflozin 100 and 300 mg and placebo were 4.5%, 6.8% and 4.7%, respectively, for those with eGFR !60 mL/min/1.73 m 2 ; for those with eGFR !45 and 560 mL/min/1.73 m 2 , 5.2%, 9.1% and 5.5% met outlier criteria for potassium, respectively 53 . Episodes where potassium elevations were considered to be clinically significant enough to be reported as AEs were less frequent overall. Such AEs were reported in 0.8%, 0.7% and 0.2% of patients with eGFR !60 mL/min/1.73 m 2 and 1.4%, 2.1% and 1.5% of patients with eGFR !45 and 560 mL/min/1.73 m 2 who were treated with canagliflozin 100 and 300 mg and placebo, respectively 53 .

Volume depletion-related AEs
Treatment with canagliflozin may be associated with a natriuretic effect as well as an osmotic diuretic effect due . Change in ACR in the study of CANA versus GLIM as add-on to metformin over 104 weeks 14,18 . ACR, albumin-to-creatinine ratio; CANA, canagliflozin; GLIM, glimepiride. to glucosuria. Therefore, data on AEs related to volume depletion (e.g., hypotension, postural dizziness, hypovolemia, dehydration, syncope and decreased urine output) were specifically collected in the clinical trials of canagliflozin 46 . In the pooled, placebo-controlled population, the incidence of AEs related to volume depletion was low (52%) across treatment groups, and most were mild or moderate in intensity 46 . The incidence of volume depletion-related AEs was higher with canagliflozin 100 and 300 mg compared with placebo in the pooled population of patients with T2DM and Stage 3 CKD (5.0%, 8.5% and 2.6%, respectively) 45 . Select populations (including patients with eGFR 560 mL/min/1.73 m 2 , patients !75 years of age and patients taking loop diuretics) are at increased risk for AEs related to volume depletion and should be monitored accordingly 52 .

Bone fractures
Patients with T2DM are at an increased risk for bone fractures compared with individuals without T2DM who have comparable bone mineral density 54,55 . Specifically, appendicular and vertebral fracture rates are higher in patients with T2DM than in other populations with comparable bone mineral density [56][57][58] .
Canagliflozin was not associated with notable differences in bone mineral density over 104 weeks 59 . In a previous analysis of a broader population, which was undertaken for the purpose of regulatory submission, canagliflozin was associated with an increased risk of fractures attributable to an excess number of fractures in the CANagliflozin cardioVascular Assessment Study (CANVAS), where participants were older and had prior history/risk of cardiovascular disease, lower baseline eGFR and higher baseline diuretic use; fractures in this population were imbalanced during the first 26 weeks of treatment 59 . Therefore, the effects of canagliflozin on fractures in patients with T2DM and CKD are of interest. In the study of canagliflozin in patients with T2DM and eGFR !30 and 550 mL/min/1.73 m 2 , the incidence of fracture AEs was low, with no imbalance across groups at Week 52 (1.1%, 1.1% and 2.2% with canagliflozin 100 and 300 mg and placebo, respectively) 19 . In the pooled, placebo-controlled studies, the incidence of fracture AEs was 0.7%, 0.6% and 0.3% with canagliflozin 100 and 300 mg and placebo, respectively, over 26 weeks 59 . The incidence of fractures was similar with canagliflozin and placebo or active comparator in patients with T2DM from the non-CANVAS studies 59 . In CANVAS, the incidence rates of fractures were 1.6, 1.6 and 1.1 per 100 patient-years of exposure with canagliflozin 100 and 300 mg and placebo, respectively, and most fracture AEs generally occurred early during treatment, with no differences in the incidence through Week 26. Further data on fracture incidence will be collected in ongoing studies.

Cardiovascular safety
Patients with T2DM are at increased risk for cardiovascular events 60 , particularly if they have comorbid CKD 61 . The ongoing CANVAS study will contribute to the evaluation of the long-term cardiovascular safety of canagliflozin compared with placebo in patients with T2DM who have an elevated risk for cardiovascular disease 47 . In a prespecified interim meta-analysis of adjudicated major cardiovascular events in Phase 2 and 3 clinical studies of canagliflozin, including CANVAS, undertaken for the purposes of regulatory submission 62 , the hazard ratio for the composite primary endpoint of time to an event of cardiovascular death, non-fatal stroke, non-fatal myocardial infarction or unstable angina requiring hospitalization for canagliflozin (both doses pooled) compared with combined active and placebo comparators was 0.91 (95% CI: 0.68, 1.22), suggesting no increased cardiovascular risk associated with canagliflozin 59 ; rates of cardiovascular events were similar with both canagliflozin doses.
In addition to the lack of increased cardiovascular risk associated with canagliflozin, it has been hypothesized that canagliflozin may have an overall favorable effect on cardiovascular disease and progression to ESRD in patients with T2DM and impaired renal function. The effects of canagliflozin treatment on cardiovascular disease and progression of diabetic nephropathy will be evaluated in two ongoing trials, including CANVAS-R (ClinicalTrials.gov identifier: NCT01989754) and the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE; NCT02065791).

Current regulatory approvals of canagliflozin in CKD
Due to the diminished efficacy of canagliflozin in patients with Stage 3B CKD (eGFR !30 and545 mL/min/1.73 m 2 ) and the need for more data on the balance between efficacy and safety in patients with Stage 3 CKD, canagliflozin is currently only indicated for glycemic control in patients with Stage 3A CKD (eGFR !45 and 560 mL/min/ 1.73 m 2 ) 52,59 . In the United States and Europe, patients with Stage 3A CKD are limited to receiving canagliflozin 100 mg 52 . In Europe, patients must have baseline eGFR !60 mL/min/1.73 m 2 to initiate canagliflozin therapy. Patients whose eGFR falls persistently 560 mL/min/ 1.73 m 2 can continue treatment with canagliflozin 100 mg; however, if eGFR falls persistently 545 mL/min/ 1.73 m 2 , treatment must be discontinued 59 . Canagliflozin is not currently recommended for patients with eGFR 545 mL/min/1.73 m 2 .
Results from ongoing studies that are enrolling patients with Stage 3B CKD, including CANVAS, CANVAS-R and CREDENCE, will provide more information on the safety of canagliflozin in patients at high risk for cardiovascular disease and in patients with impaired renal function, as well as information on the potential cardiovascular and renal protective effects of canagliflozin.

Summary
The renal safety findings from the canagliflozin clinical program summarized in this review indicate that canagliflozin is generally well tolerated in patients with varying baseline kidney function status. While the majority of patients treated with canagliflozin had small initial reductions in eGFR with commensurate increases in serum creatinine that occurred shortly after initiation of treatment and were consistent with the known hemodynamic changes induced by SGLT2 inhibitors, these changes were generally transient and stabilized or attenuated over time. Reductions in ACR were also seen with canagliflozin treatment, possibly due to reduced intraglomerular pressure, raising the possibility of longterm renal protection and reductions in the risk of kidney failure. These results, along with reductions in systolic BP, suggest that canagliflozin may have an overall favorable effect on cardiovascular disease risk and the progression of CKD. Effects on renal parameters with canagliflozin treatment were similar on an absolute basis in patients with normal renal function and those with moderate renal impairment across Phase 3 studies. Changes in renal function parameters were also similar regardless of age, despite the fact that older patients tended to have lower baseline eGFR. In addition, smaller but meaningful reductions in HbA 1c and body weight were observed in patients with reduced kidney function, whereas BPlowering effects appeared to be preserved. Taken together, the current data suggest that canagliflozin may have renal and/or cardiovascular protective effects in T2DM, and large outcome studies are currently underway to evaluate these potential effects of canagliflozin treatment.

Transparency
Declaration of funding This review article reports data from previously published studies funded by Janssen Research & Development, LLC. The authors prepared the manuscript with medical writing assistance funded by Janssen Global Services, LLC.
Declaration of financial other/relationships V.P. has disclosed that he is supported by a Senior Research Fellowship from the National Health and Medical Research Council of Australia; has served on advisory boards and/or spoken at scientific meetings sponsored by Janssen, Baxter, AbbVie, Astellas, Bayer, Bristol-Myers Squibb, Boehringer Ingelheim, AstraZeneca, Eli Lilly, Merck and GlaxoSmithKline; and has a policy of honoraria going to his employer. M.J. has disclosed that she is supported by a Career Development Fellowship from the National Health and Medical Research Council of Australia and the National Heart Foundation, has received speaker's fees from Amgen and Roche, and funding for a clinical trial from Gambro; and serves on steering committees for trials funded by Janssen; all honoraria are contributed directly to clinical research programs. U.V. and G.M. have disclosed that they are full-time employees of Janssen Research & Development, LLC. CMRO peer reviewers on this manuscript have no relevant financial or other relationships to disclose.